Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10422731 | 0.98 | CYP11B1 (0.48) | CYP11B1CYP11B2MAOAMAOBCYP19A1 | |
| SCHEMBL29413869 | 0.86 | CYP11B2 (0.43) | CYP11B1CYP11B2MAOAMAOBCYP19A1 | |
| SCHEMBL8188259 | 0.86 | CYP11B2 (0.43) | CYP11B1CYP11B2MAOAMAOBCYP19A1 | |
| SCHEMBL9583120 | 0.81 | ALDH1A1 (0.37) | CYP11B1CYP11B2MAOAMAOBKDM4E | |
| SCHEMBL9573518 | 0.81 | CA1 (0.42) | CYP11B1CYP11B2CYP19A1KDM4EALDH1A1 | |
| SCHEMBL28307317 | 0.78 | STS (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL9572934 | 0.78 | MEN1 (0.38) | MAOAKDM4EALDH1A1LMNA | |
| SCHEMBL30025550 | 0.76 | ADRA2A (0.34) | GAAKDM4EALDH1A1 | |
| SCHEMBL7938077 | 0.76 | ADRA2A (0.34) | GAAKDM4EALDH1A1 | |
| SCHEMBL251439 | 0.74 | MAOA (0.47) | MAOAMAOBGAACHRNA7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367123-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | Glenmark Specialty S.A. (CH) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
| CN-111621805-B | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2022-02-18 | — | — | CN | disclosed |
| US-11197858-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| CN-111621805-A | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2020-09-04 | — | — | CN | disclosed |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| CN-106795118-B | Heterocyclic compound and their purposes as relevant orphan receptor (ROR) the GAMMA-T inhibitor of retinoids | 武田药品工业株式会社 | 2019-10-08 | — | — | CN | disclosed |
| CN-106795118-A | Heterocyclic compound to they as related orphan receptor (ROR) the GAMMA T inhibitor of retinoids purposes | 武田药品工业株式会社 | 2017-05-31 | — | — | CN | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-2665727-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5231181-A | PROCESS FOR THE PREPARATION OF (8AS,12AS,13AS)-DECAHYDROISOQUINO ((2,1-G) (1,6)-NAPHTHYRIDIN-8-ONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1993-07-27 | — | — | US | disclosed |
| US-5229387-A | Cardiovascular disorders, alpha2-adenoreceptor antagonist or hydroxytryptamine receivers as hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0524004-A1 | Decahydro-8H-isoquino[2,1-g][1,6]naphthyridine and decahydrobenzo[a]pyrrolo[2,3-e]quinolizine derivatives | SYNTEX (U.S.A.) INC. (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0505183-A2 | Process for the preparation of (8aS,12aS,13aS)-decahydroisoquino[2,1-g][1,6]-naphthyridin-8-one derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| US-4678792-A | ANTITHROMBIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-07-07 | — | — | US | disclosed |
| EP-0154842-A2 | Medicament containing quaternary 3,4-dihydroisoquinoline salts | Dr. Karl Thomae GmbH (DE) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197858-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | CYP11B1 1415/4885CYP11B2 1074/4885MAOA 179/4885 |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | CYP11B1 1415/4885CYP11B2 1074/4885MAOA 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.